Medications

Drug companies forge partnerships with top schools

(AP)—Pharmaceutical companies that can no longer rely on lucrative patents to drive profits are increasingly teaming up with academia in search of the next big drug discovery.

Medications

FDA clears anticlotting drug Eliquis

The Food and Drug Administration says it has approved the anticlotting drug Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc. It's a potential blockbuster drug in a new category of medicines to prevent strokes ...

Medications

Bristol-Myers, Pfizer's Eliquis approved in Japan

Regulators in Japan have approved sales of an anticlotting drug called Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc., that's a potential blockbuster in a new category of medicines to prevent strokes and heart ...

Medications

Stop-smoking drug Chantix may carry heart risks, FDA warns

(HealthDay)—People who take the prescription quit-smoking drug Chantix may be at higher risk for cardiovascular problems, and doctors should weigh the risks of the drug against it benefits, the U.S. Food and Drug Administration ...

Medications

Drugmaker Ranbaxy halts generic Lipitor production

Problem-plagued Ranbaxy Pharmaceuticals Inc. has halted production of generic cholesterol drug Lipitor while it investigates how tiny glass particles got into the ingredients used for dozens of batches of the drug that were ...

Arthritis & Rheumatism

Xeljanz approved for rheumatoid arthritis

(HealthDay)—Xeljanz (tofacitinib) has been approved by the U.S. Food and Drug Administration to treat symptoms of rheumatoid arthritis (RA) among people who can't tolerate, or haven't been helped by, the drug methotrexate.

Other

Pfizer 3Q profit falls 14 pct on generic Lipitor (Update)

(AP)—Drug giant Pfizer Inc. said Thursday that its third-quarter profit fell 14 percent as sales plunged, mainly due to U.S. generic competition to cholesterol fighter Lipitor, long the world's top-selling drug.

Medications

Pfizer will buy NextWave Pharma for up to $700M

(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

Diseases, Conditions, Syndromes

5-question survey may increase COPD diagnoses

A simple, five-question patient-administered survey (COPD-PS) may lead to increased diagnoses of chronic obstructive pulmonary disease (COPD).

page 3 from 6